CN106265753A - Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of Leydig's cell tumor, health product or food - Google Patents
Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of Leydig's cell tumor, health product or food Download PDFInfo
- Publication number
- CN106265753A CN106265753A CN201610809046.7A CN201610809046A CN106265753A CN 106265753 A CN106265753 A CN 106265753A CN 201610809046 A CN201610809046 A CN 201610809046A CN 106265753 A CN106265753 A CN 106265753A
- Authority
- CN
- China
- Prior art keywords
- fab
- chrysomyiame gacephala
- goods
- gacephala
- chrysomyiame
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 235000013305 food Nutrition 0.000 title claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 11
- 241000522620 Scorpio Species 0.000 claims abstract description 6
- 239000009490 scorpio Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000001629 suppression Effects 0.000 claims description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 235000001014 amino acid Nutrition 0.000 abstract description 6
- 150000001413 amino acids Chemical class 0.000 abstract description 6
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 229920001661 Chitosan Polymers 0.000 abstract description 2
- 230000000973 chemotherapeutic effect Effects 0.000 abstract description 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 2
- 229930195729 fatty acid Natural products 0.000 abstract description 2
- 239000000194 fatty acid Substances 0.000 abstract description 2
- 150000004665 fatty acids Chemical class 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 31
- 238000009395 breeding Methods 0.000 description 9
- 230000001488 breeding effect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000003128 head Anatomy 0.000 description 5
- 241000202815 Chrysomya megacephala Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000002917 insecticide Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000257161 Calliphoridae Species 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000003448 neutrophilic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108050008874 Annexin Proteins 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000010981 turquoise Substances 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000134068 Mesostigma Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000270934 Rana catesbeiana Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000003274 Sertoli cell tumor Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010060926 abdominal symptom Diseases 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000028210 stromal sarcoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Insects & Arthropods (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of therapeutic field of tumor, particularly relate to Chrysomyiame gacephala (Fab.) goods for preparing the application in the treatment medicine of Leydig's cell tumor, health product or food.The Chrysomyiame gacephala (Fab.) goods of the present invention are a kind of natural product, and Chrysomyiame gacephala (Fab.) goods effective ingredient is Chrysomyiame gacephala (Fab.) Scorpio, and modern medicine study proves: in Chrysomyiame gacephala (Fab.) containing protein, fat, chitosan, containing antibacterial peptide and 18 kinds of aminoacid.Including all effective ingredient of Chrysomyiame gacephala (Fab.) Scorpio in the Chrysomyiame gacephala (Fab.) dry powder of the present invention, Chrysomyiame gacephala (Fab.) extract is mainly with fatty acid and/or protein, polypeptide, aminoacid etc..It has been investigated that, Chrysomyiame gacephala (Fab.) goods can effectively suppress Leydig's cell tumor to grow, and Chrysomyiame gacephala (Fab.) goods do not have drug resistance and the toxic and side effects thereof of chemotherapeutic conventional clinically.
Description
Technical field
The present invention relates to a kind of therapeutic field of tumor, particularly relate to Chrysomyiame gacephala (Fab.) goods for preparing treatment Leydig's cell tumor
Application in medicine, health product or food.
Background technology
Chrysomyiame gacephala (Fab.) is Calliphoridae (Calliphoridae) insecticide chrysomyia megacephala (big head golden fly) (ChrysomyiamegacephalaFab.)
Or the dry larva body of other nearly edge insecticides, the most on the books in medical book in ancient times, it is used for treating infantile malnutrition, pustule ulcer.
Record Chrysomyiame gacephala (Fab.) at present and there is following pharmacological action: 1. antiasthmatic effect, the total amino acids contained by Chrysomyiame gacephala (Fab.) is to relieving asthma
Effective ingredient；2. the effect that pair intestinal is smooth, Chrysomyiame gacephala (Fab.) ethanol extraction and Chrysomyiame gacephala (Fab.) total amino acids crude extract are to histamine institute
The ileum smooth muscle spasm of cause isolated rabbit and Cavia porcellus all has significantly strives convulsion effect；3. toxicity, the toxicity of Chrysomyiame gacephala (Fab.) is the least.
Chinese invention patent application (application number CN200510060277.4 applying date 2005.08.04) one has anti-swollen
The cultural method of tumor biological activity fly larvae.The fly larvae of cultivation has liver through The National Center for Drug Screening's in the past few years repeated detection
Cancer, breast carcinoma, ovarian cancer, cervical cancer, pulmonary carcinoma, gastric cancer, etc. growth of tumour cell have the strongest suppression ratio, its anti-tumor biological live
Property is all 75%～97%.
Chinese invention patent application (application number CN200710067951.0 applying date 2007.04.10) discloses a class and resists
Neoplastic compound, this component extracting and developing from the fly larvae that allogenic material is induced obtains, and has suppression people's promyelocytic leukemia
HL-60 and the effect of human pulmonary epithelial cells propagation growth.
Chinese invention patent application (application number CN201310223817.0 applying date 2013.06.06) discloses a kind of five
Paddy worm antineoplastic new usage, is showed by the effect of Chrysomyiame gacephala (Fab.) suppression mouse tumor weight, and Chrysomyiame gacephala (Fab.) can suppress tumor cell
Growth, tumor cell is had lethal effect, it is possible in preparing antitumor drug or health product apply, specifically disclose little
The growth inhibited of Mus euphorbia egg decoctum.
Leydig's cell tumor, is the tumor of a kind of generation of being cancerated by Interstitial cell.Support the size difference of Leydig's cell tumor very
Greatly, about average diameter 10cm.The incidence rate of abdominal mass is high far beyond Sertoli cell tumor of ovary, reaches 32%～46%. and reports that minority swells
Tumor can twist or rupture, and colic symptoms occurs.Diameter of tumor is less than 5cm, clinical general without abdominal symptoms, during inspection also
Easily it is left in the basket, is often just found when accidental or laparotomy exploration.
Summary of the invention
First purpose of the present invention is to provide Chrysomyiame gacephala (Fab.) goods answering in the medicine preparing treatment Leydig's cell tumor
With.
Second object of the present invention is to provide Chrysomyiame gacephala (Fab.) goods in the health product preparing suppression Leydig's cell tumor
Application.
Second object of the present invention is to provide Chrysomyiame gacephala (Fab.) goods answering in the food preparing suppression Leydig's cell tumor
With.
As preferably, above-mentioned Chrysomyiame gacephala (Fab.) goods be Chrysomyiame gacephala (Fab.) dry powder and or Chrysomyiame gacephala (Fab.) extract and Chrysomyiame gacephala (Fab.) dry powder
With or the preparation prepared of Chrysomyiame gacephala (Fab.) extract.
As further preferably, described preparation is capsule, tablet, pill, powder, compound granule, health promoting wine, albumen
Powder, oral liquid or lyophilized powder.
As preferably, above-mentioned Chrysomyiame gacephala (Fab.) extract includes Chrysomyiame gacephala (Fab.) Scorpio or the water extract of Chrysomyiame gacephala (Fab.) dry powder and organic
One or more in solvent extractable matter.
As further preferably, the described organic solvent in extractive with organic solvent includes in ethanol, petroleum ether or hexane
One or more.
The Chrysomyiame gacephala (Fab.) goods of the present invention are a kind of natural product, and Chrysomyiame gacephala (Fab.) goods effective ingredient is Chrysomyiame gacephala (Fab.) Scorpio, existing
Prove for medical research: in Chrysomyiame gacephala (Fab.) containing protein, fat, chitosan, containing antibacterial peptide and 18 kinds of aminoacid.The present invention's
Including all effective ingredient of Chrysomyiame gacephala (Fab.) Scorpio in Chrysomyiame gacephala (Fab.) dry powder, Chrysomyiame gacephala (Fab.) extract is mainly with fatty acid and/or egg
White matter, polypeptide, aminoacid etc..It has been investigated that, Chrysomyiame gacephala (Fab.) goods can effectively suppress Leydig's cell tumor to grow, and Chrysomyiame gacephala (Fab.) system
Product do not have drug resistance and the toxic and side effects thereof of chemotherapeutic conventional clinically.
Detailed description of the invention
Embodiment 1
1, plant fly to select
Zoology is identified: Calliphoridae Calliphoridae insecticide chrysomyia megacephala (big head golden fly) Chrysomyia megacephala
(Fab.).Become fly body length 8～11 millimeters, turquoise, head width, top black；Compound eye is big, peony, frontalia maroon, face
Orange-yellow with buccal, feeler and palpuli brown.Breast, abdominal part turquoise, with purple gloss.After 1st uromere and the 2nd, 3 uromere
Edge black.Forehead and the middle bar of female fly the most slightly protrude in center.The facet of big shape is arranged at male fly compound eye top 2/3,
Lower section 1/3 is then the facet of little shape, and the two interface is clear.Prothoracic spiracles black, mesostigma is light brown；There is valve.Proxacalypteron
Band brown, above has little Mao.Yellow-white during larval maturation, front end is tapering, and rear end is truncated.Body segment 14, head 1 saves, and chest 3 saves, abdomen
Portion 10 saves, but generally only sees 8 joints.The ring that body surface is formed by clavula.Rear valve is slightly higher than surface, and more flat in top, spiracular annulus is not
Completely；Rear valve spacing is not more than the transverse diameter of rear valve；The 1st vertical shape of ostium；Front valve has 10 13 finger-like and dashes forward.
2, plant fly to gather
(1) making of fly case is planted: can select wooden, glass, ceramic making, circular or rectangle, top stays one
The mouth of individual diameter 25 centimetres, and make the netted lid that a use is ventilative, escape in case planting fly.
(2) configuration of fly feedstuff is planted: milk powder+brown sugar, 1:1 mixes, and the water adding 15% is in harmonious proportion, and is positioned in kind of fly case.
(3) opening kind of the netted lid of fly case, be placed in 28--38 degree Celsius, humidity is less than in the environment of 65%.
The chrysomyia megacephala (big head golden fly) allowing the external world is looked for food in entering case, undesirable fly kind is carried out sorting and abandons, and cover net
Shape lid so that it is look for food in being stranded in kind of fly case, lay eggs.
3, cultivation hardware and breeding feed
(1) fly room is built: by cultivation scale, can select masonry, glass, plastics, steel frame construction material, overhead 2 meters
It is spaced 1.5--2 rice on the body of wall of left and right and vent window is set, for preventing other flies or insecticide from entering, be preferably provided with screen window with extraneous
Isolation, above box for breeding, a metric system becomes mobilizable ventilation shaft, it is simple to gas sampling, prevents emission of bad smell from polluting environment,
Waste gas unification is discharged after being processed by ozone deodorizer.For preventing fly kind from entering gas sampling pipeline, preferably set at each air inlet
Put screen window to cut off.
(2) box for breeding makes: can select wooden, ceramic, cement material, make rectangular box, bottom arranges sealing
Sealing device, stays the circular hole of diameter 30--40 centimetre above casing,.It is provided with sewage collecting below each box for breeding to lead to
Road, unified entrance after cesspool processes is discharged.
(3) insulation: for meeting the standardisation requirements of cultured product, can set up heat, cooling installation.When sweltering heat, season can
In face, fly roof, anti-sunshading facility is set.
(4) breeding feed: haslet, fresh-water fishes, bull frog, milk powder, Mel.
4, breeding technique step
(1) fly kind: the fly kind of collection is transplanted to carry in the kind fly case being placed with fresh-water fishes the previous day, cultivates 2 days, treats that it is at case
Inside lay eggs.
(2) fly blow is collected: treat that kind of fly lays eggs in fly kind case, fly blow can be collected, transfer to the fly room added with feedstuff
Carrying out in box for breeding hatching, cultivating, the ratio of feedstuff and fly blow is every 5 grams of fly blows, adds the feedstuff of 15 kilograms.
(3) hatching cultivation: after fly blow hatching, required feedstuff can be obtained in box for breeding, it is generally required to 72 hours, worm
Body grows to length 1--1.2 centimetre, during diameter 2.5--3 millimeter.
(4) active catalytic: in box for breeding add with 200 milliliters of prewired 5% sucrose (w/w) aqueous solutions and 1% surpass
Superoxide dismutase (LA-SOD) (activities of the enzyme systems is more than 3,000,000 units/gram) 500 milliliters, takes out live body Chrysomyiame gacephala (Fab.) after 2 hours,
Repeatedly rinse well with clear water, at once put into the refrigerator-freezer quick-freezing of less than 38 degrees Celsius.
(5) cleaning-drying: low-temperature quick-freezing two days later, takes out, and melts, more carefully cleans, drain away the water in clear water, uses
Vacuum dehydrating at lower temperature equipment is dried to moisture less than 10%.
Test example 1
One, experiment purpose
Evaluate the antitumor engineering Chrysomyiame gacephala (Fab.) extracorporeal anti-tumor function to mice MLTC-1 Leydig's cell tumor.
Application AnnexinV-FITC/PI-FCM quantitative analysis Chrysomyiame gacephala (Fab.) sample inducing mouse MLTC-1 Leydig's cell tumor is sent out
Raw apoptosis.Two, major experimental instrument and material,
1, material
1.1.1 JEG-3 and cultivation mice MLTC-1 Interstitial cell tumor cell strain thereof, purchased from Shanghai, the Chinese Academy of Sciences is thin
Born of the same parents storehouse.Cell grows in F12K and the RPMI-1640 culture fluid containing the superfine new-born calf serum of inactivation of 10%, growth of taking the logarithm
Phase cell is tested.In incubator, the concentration of carbon dioxide is 5%, temperature 37 DEG C, saturated humidity.
1.1.2 the lyophilized powder after medicine and reagent Chrysomyiame gacephala (Fab.) water carry.AnnexinV-FITC/PI apoptosis test kit is Nanjing
Triumphant base Products；RNaseA, trypsin GIBCO).
2, key instrument
BD flow cytometer BD FACSCaliburTM
Three, experimental technique and step
1. drug treating is taken the logarithm the cell of trophophase, adds Chrysomyiame gacephala (Fab.) water and carries lyophilized powder, by final concentration of 0,1mg/
Ml, after 0.25mg/ml, 0.5mg/ml and cell hatch 24,48,72 hours jointly, digest with 0.25% trypsin,
Make unicellular, then rinse 2 times with 1 × PBS, centrifugal rear standby.
2.AnnexinV-FITC/PI-FCM detection prepares dye liquor and buffer in advance, is placed on ice, takes standby cell
Count, every 105～106Cell adds 500ul Binding Buffer suspension cell, adds 5ul Annexin V-
After FITC mixing, add 5ul PI mixing；Room temperature, lucifuge, reaction 15 minutes, upper machine testing.
3, data and graphical analysis
On the FCM analysis chart of two dimension, cell is divided into four subgroups: lower-left (LL) quadrant, Annexin V-FITC-/PI-
For living cells group (V)；Bottom right (LR) quadrant, Annexin V-FITC+/PI-is apoptotic cell (AP), and this district's cell has typical case
Apoptotic cell feature: including that cell reduces with Assessment of Nuclear Volume, Chromatin condensation is fine and close, has crescent shape karyomorphism to become, on cell membrane
Microvillus disappear；Upper right (UR) quadrant, AnnexinV-FITC+/PI+ cell has been provided with the feature of non-viable non-apoptotic cell: cell membrane
Rupture, organelle swelling, vacuolation in kytoplasm, for secondary necrosis cell (N)；Upper left (UL) quadrant, AnnexinV-FITC-/
PI+ is to cultivate the mechanical damage cell (O) occurred in operating process.
Four, experimental result
Concentration and the time impact on inducing mouse MLTC-1 Leydig's cell tumor apoptosis
Note: V: lower-left (LL) quadrant, living cells group's percentage；AP: bottom right (LR) quadrant, percentage shared by apoptotic cell
Ratio；N: upper right (UR) quadrant, secondary necrosis cell percentage；O: upper left (UL)
Five: experimental result
Testing result (table 1) shows, sample, at 72 hours, at 0.25mg and 0.5mg of low concentration, obvious apoptosis occurs
Phenomenon, there were significant differences, and normal live cells gradually decreases simultaneously.
Test example 2
Pay * *, female, 61 years old, Xiacheng District, Hangzhou, gastro-intestinal stromal glucagonoma.
Patient found gastrointestinal cell plastid tumor between trouble, excision, chemotherapy in 2008.
Recurrence in 2013, oral Erlotinib controls, and finds drug resistance after seven months, and at liver.Pelvic cavity finds metastasis, examination
With SU11248, three months, metastasis position continued to increase, and in July, 2014, during inspection, found that liver has dark space, many places, and the maximum is
4.8 centimetre.Pelvic cavity has 1.4*1.0 and 1.3*1.0 centimetre two, and adnexa has 2.5*1.5 centimetre of focus.Neutrophilic granulocyte
0.9%of WBC, and skin rash occurs, more serious digestive tract reaction, by drug withdrawal.
Starting aspiration in August, 2014 and take primary capsule (Chrysomyiame gacephala (Fab.) extract), on October 6th, 2014 checks, liver
Focus narrows down to 2.7*1.8, and thin-walled circle is clear, and adnexa narrows down to 2.1*1.5, and neutrophilic granulocyte goes back up to 18, in February, 2015
Check on the 6th, neutrophilic granulocyte is returned to 61.2%.(normal value 50 70).In period of taking medicine, patient without discomfort, the mental status,
Appetite takes a turn for the better substantially.At present also in after treatment.
Test example 3
Yin * *, sex: man, age: 59, address: Meishan, changxing, zhejiang Province；
Within 2005, it is diagnosed as pelvic cavity malignant stromal tumors year, and at Shanghai Long March Hospital's row tumor of pelvic cavity radical correction, postoperative extensive
Multiple good.In June, 2007 recurs hepatic metastases, digital rectal examination away from anus 5 centimeters antetheca one lump, about 4*2.5 centimetre, OK
Miles art, is followed by being treated by hospital's targeted drug " Iressa ", drug resistance occurs, and have serious side effects, by stopping after taking medicine 1 year
Medicine.
Medical record brief introduction:
After patient is because of drug resistance reaction drug withdrawal, in October, 2008 checks, finds there are two shades in liver, and size is respectively
2.0*1.4 centimetre and 1.1*1.0 centimetre, at the end of Year 2008, introduce through friend, accept oral antitumor Chrysomyiame gacephala (Fab.) treatment, treatment
Period is the most auxiliary treats in other drug and means.Checking after treating six months, in liver, shade one disappears.One narrows down to
0.77*0.4 centimetre.Patient experiences stable disease, does not occurs rebound phenomenon at present, and self-induction is without significant discomfort, according to the inspection of image recently
Looking into report display, conditions of patients is effectively controlled, and concurrent hepatic metastases stove disappears the most substantially, and spiritual and physical situation recovers good
Good.
Claims (7)
1. Chrysomyiame gacephala (Fab.) goods application in the medicine preparing treatment Leydig's cell tumor.
2. Chrysomyiame gacephala (Fab.) goods application in the health product preparing suppression Leydig's cell tumor.
3. Chrysomyiame gacephala (Fab.) goods application in the food preparing suppression Leydig's cell tumor.
4. according to the application described in claim 1 ~ 3 any one claim, it is characterised in that Chrysomyiame gacephala (Fab.) goods are Chrysomyiame gacephala (Fab.)
Dry powder and or Chrysomyiame gacephala (Fab.) extract and Chrysomyiame gacephala (Fab.) dry powder and or the preparation prepared of Chrysomyiame gacephala (Fab.) extract.
Application the most according to claim 4, it is characterised in that preparation is capsule, tablet, pill, powder, compound granular
Agent, health promoting wine, egg albumen powder, oral liquid or lyophilized powder.
Application the most according to claim 4, it is characterised in that Chrysomyiame gacephala (Fab.) extract includes that Chrysomyiame gacephala (Fab.) Scorpio or Chrysomyiame gacephala (Fab.) are done
One or more in the water extract of powder and extractive with organic solvent.
Application the most according to claim 6, it is characterised in that the organic solvent in extractive with organic solvent includes ethanol, stone
One or more in oil ether or hexane.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610809046.7A CN106265753A (en) | 2016-09-08 | 2016-09-08 | Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of Leydig's cell tumor, health product or food |
| PCT/CN2017/100684 WO2018045959A1 (en) | 2016-09-08 | 2017-09-06 | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610809046.7A CN106265753A (en) | 2016-09-08 | 2016-09-08 | Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of Leydig's cell tumor, health product or food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106265753A true CN106265753A (en) | 2017-01-04 |
Family
ID=57709735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610809046.7A Pending CN106265753A (en) | 2016-09-08 | 2016-09-08 | Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of Leydig's cell tumor, health product or food |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106265753A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045959A1 (en) * | 2016-09-08 | 2018-03-15 | 黄玉水 | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991608A (en) * | 2010-11-19 | 2011-03-30 | 浙江省医学科学院 | Fly maggot extractive as well as preparation method and application thereof |
| CN103271947A (en) * | 2013-06-06 | 2013-09-04 | 四川科伦新光生物科技开发有限公司 | Novel antitumor application of maggot |
-
2016
- 2016-09-08 CN CN201610809046.7A patent/CN106265753A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991608A (en) * | 2010-11-19 | 2011-03-30 | 浙江省医学科学院 | Fly maggot extractive as well as preparation method and application thereof |
| CN103271947A (en) * | 2013-06-06 | 2013-09-04 | 四川科伦新光生物科技开发有限公司 | Novel antitumor application of maggot |
Non-Patent Citations (2)
| Title |
|---|
| 云贵: "水仙子昆虫蛋白研究概况", 《上海医药》 * |
| 华允芬等: "特种五谷虫脂肪酸的体外抗肿瘤、抗HIV-1整合酶活性及组成分析", 《昆虫学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045959A1 (en) * | 2016-09-08 | 2018-03-15 | 黄玉水 | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104130958B (en) | One bacillus subtilis and the application in preventing and treating root knot nematode on tree peony disease thereof | |
| CN105219655B (en) | Aspergillus flavus biocontrol bacterial strain and its application of aflatoxin are not produced to fungicide resistance and | |
| CN103756916B (en) | A kind of Acremonium terricola mutant strain and application thereof | |
| CN106344615A (en) | Application of Larva Chrysomyiae products to preparation of drugs, health care products or foods for treating non-small cell lung cancers | |
| CN106109483A (en) | There is the glycol group/triol group rare ginsenoside compositions of anti-tumor activity | |
| CN101418279A (en) | Flavonoid-rich tissue from neomarica gracilis | |
| CN106420827A (en) | Application of Larva ChrysomyiamegacephalaFab. product in preparing dugs, health care products or foods for treating colon cancer | |
| CN103333858B (en) | Gleevec-resistant gastrointestinal stromal tumor cell line, method thereof, and nude mouse transplantation tumor model thereof | |
| CN106173209A (en) | A kind of nematode-destroying fungus powderous preparations and application thereof | |
| CN106265753A (en) | Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of Leydig's cell tumor, health product or food | |
| CN101245334A (en) | Technique for suspension cultivation of algam dendrobium nobile embryoid of medicinal effective composition of native plant strain | |
| CN105325466B (en) | A kind of composition for inducing plant disease-resistant and coordinate plant growth, and its preparation method and application | |
| CN110327328A (en) | Application of 25 β--23 β of the secondary cyclobutenyl-isobutyl acyloxy mibemycin derivative in antitumor | |
| CN106754427B (en) | Penicillium lanophorum Kong Junxin strain and domestication method thereof | |
| CN106420829A (en) | Application of maggot product to preparation of medicine, health care product or food for treating gliocytoma | |
| CN107142217A (en) | A kind of biological pesticide for being used to reduce crops aflatoxin content | |
| CN104450630A (en) | Method for culturing goose parvovirus by using goose embryo fibroblast line | |
| CN104146257B (en) | Biological reinforced cell nutritious element is preparing the application in AntiHIV1 RT activity functional food | |
| CN107496473A (en) | Application of the okra water extract in digestive tract function is protected | |
| CN108611279B (en) | Domestication method of sorangium cellulosum, domesticated sorangium cellulosum and application | |
| CN108403941B (en) | Traditional Chinese medicine composition for treating pancreatic cancer and preparation method and application thereof | |
| CN102086446A (en) | Strain of Adenoviridae and application thereof | |
| CN109679914A (en) | A kind of strain of human mesothelial cell vicious transformation and its application of multi-walled carbon nanotube induction | |
| WO2019182313A1 (en) | Black rice germination liquid having anti-inflammatory effect and method for preparing same | |
| Ullah et al. | Polysaccharides derived from Deglet Noor dates modulate amoxicillin-induced dysbiosis and enhance intestinal barrier function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
| RJ01 | Rejection of invention patent application after publication |